SARS-CoV-2 (COVID-19) workforce testing solutions

Promote health and safety as employees return to the work site

Quest Diagnostics®

Quest is committed to **delivering quality diagnostic insights** and supporting the effort to fight COVID-19.

Quest Diagnostics has the experience and expertise to help you promote workforce health and safety



Laboratory testing from Quest Diagnostics impacts the lives of 30% of American adults each year.

Quest has 4 decades of experience leading infectious disease testing during public health emergencies, including Zika, SARS, and H1N1 influenza.

Our network of labs operates 24 hours a day, 365 days a year.

Our fleet of 25 aircraft and over 3,700 courier vehicles quickly move testing specimens around the nation.

We have nationwide access with 2,250 Patient Service Centers (PSCs), retail partner locations, and at-home collection options.

Plus, Quest has an employer population health team that has 20 years of experience partnering with thousands of employers.

Quest's COVID-19 response

On March 9, 2020, 2 days before the virus was labeled a worldwide pandemic, Quest launched a lab-developed COVID-19 test. FDA EUA was received for the test on March 17, 2020.

FDA EUA for COVID-19 Nasal Specimen Self-Collection Kit received in May 2020.

During the peak of the pandemic, Quest laboratory testing accounted for nearly 50% of all COVID-19 testing in the US.

Our labs have the capacity to run 300,000 molecular diagnostic tests a day with an average turnaround time of 1-2 days.*

Required results of COVID-19 tests completed with Quest are automatically reported to public health agencies.

Quest currently supports hundreds of employers with our workforce COVID-19 testing solutions, with the ability to capture custom consent and send results data to approved employer contacts.

*Turnaround time refers to the expected number of days required to collect, transport, perform testing on, and report results for a specimen. It begins at the end of the day on which a specimen was collected and ends at the end of the day on which we report the result. For instance, a specimen collected at 11 AM on a Monday and reported electronically to a healthcare provider at 2 PM on a Wednesday would reflect a turnaround time of 2 days. We provide the expected turnaround time for specimens arriving into our laboratories on a given day (versus a historical perspective for results being reported that day) so that providers and the public can make informed decisions before they order a test. Turnaround time can fluctuate with demand, supplies and other factors, and vary by region.

Testing and specimen collection capabilities

With the exception of on-site temperature checks, all COVID-19 testing programs also include: custom participant consent; results feed to employers or third party administrators; reporting to state and local agencies; eligibility management; online and telephonic scheduling; digital and paper participant results; and Personal Protective Equipment (PPE) for on-site events (if applicable).

Nucleic Acid Amplification Testing (NAAT) for active infection

- A self-collection nasal swab that is returned to a Quest lab for testing
- The type of test with the highest sensitivity; results available within 1-2 days*
- Can be shipped directly to employees' homes for unobserved self-collection
- Bulk kit supply can be shipped to work site locations to use as needed
- Supervised self-collection at retail locations also available
- Work site testing events available upon request for locations with over 100 employees

Rapid antigen testing surveillance for active infection

- A virtually guided self-collection nasal swab that is tested at the participant's home
- Faster turnaround time than NAAT, but not as sensitive
- Ideal for routine surveillance screening
- Can be shipped directly to work sites or employees' homes for virtually guided self-collection
- Individuals who are symptomatic or test positive have access to a confirmatory NAAT

Antibody testing for prior infection

- A venipuncture blood draw to indicate the level of IgG antibodies present in the blood
- Available to be collected at Quest PSC locations nationwide
- Also available as part of yearly biometric screening panel to help get employees back to care

Temperature checks for symptom monitoring

- Work site temperature screenings performed by Quest Diagnostics staff
- Availability of on-site staffing is dependent on Quest provider capacity

Quest Diagnostics®

We're here to help you streamline COVID-19 testing and care for your workforce.

COVID-19 workforce solutions from Quest Diagnostics can help your employees:

- Monitor COVID-19 symptoms with work site temperature checks
- Detect active COVID-19 infections with molecular (NAAT) testing or rapid antigen testing
- Understand their immune response to a recent or prior infection with antibody testing
- Easily access a COVID-19 vaccine with on-site vaccination events

For more information, contact your Quest Representative or email PopulationHealth@QuestDiagnostics.com.

For information on workplace safety with regard to COVID-19 and offering testing and/or vaccines to employees, consult your legal counsel.

- The antibody tests and the molecular tests (together "All tests") have not been FDA cleared or approved;
- All tests have been authorized by FDA under EUAs for use by authorized laboratories;
- The antibody tests have been authorized only for the detection of IgG antibodies against SARS-CoV-2, not for any other viruses or pathogens;
- The molecular tests have been authorized only for the detection of nucleic acid from SARSCoV-2, not for any other viruses or pathogens; and,
- All tests are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of in vitro diagnostics for detection and/or diagnosis of COVID-19 under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb-3(b)(1), unless the authorization is terminated or revoked sooner.

- The vaccines have not been approved or licensed by FDA, but have been authorized for emergency use by FDA, under an EUA to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 18 years of age and older; and
- The emergency use of the vaccines is only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product under Section 564(b)(1) of the FD&C Act unless the declaration is terminated or authorization revoked sooner.